BioLife Solutions, Inc. (BLFS) Stock Score, Valuation & Financial Research
BioLife Solutions, Inc. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 32/100.
Quick answer for BLFS
BioLife Solutions, Inc. currently has a Wall Street Score of 32/100. The stored market price is $36.11. Its financial score is 34/100. Its valuation score is 10/100. These figures are a research snapshot, not a buy or sell recommendation.
What BioLife Solutions, Inc. does
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovati
BLFS financial snapshot
- Wall Street Score:
- 32/100
- Current price:
- $36.11
- Market capitalization:
- $1.76B
- Revenue:
- $102.8M
- Net income:
- $50.4M
- Free cash flow:
- $416K
- Cash:
- $24.0M
- Total debt:
- $15.7M
- EPS:
- 1.03
- P/E ratio:
- 34.9x
- Financial score:
- 34/100
- Valuation score:
- 10/100
- Revenue score:
- 45/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $416K, showing positive cash generation.
- The balance sheet shows $24.0M of cash versus $15.7M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 34/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BLFS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.